Harmony Biosciences Holdings, Inc.
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
HRMY$33.55-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| | | | | | | |
|---|---|---|---|---|---|---|
| | Six Months Ended June 30, | |||||
| · 2025 · 2024 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES · · | ||||||
| Net income | | $85,336 | | $49,925 | ||
| Adjustments to reconcile net income to net cash used in operating activities: | | | | |||
| Depreciation | | 13 | | 254 | ||
| Intangible amortization | | 11,922 | | 11,922 | ||
| Acquired in-process research & development (IPR&D) expense | | | 15,000 | | | 42,595 |
| Stock-based and employee stock purchase compensation expense | | 23,954 | | 21,482 | ||
| Stock appreciation rights market adjustment | | (110) | | (85) | ||
| Debt issuance costs amortization | | 329 | | 356 | ||
| Deferred taxes | | | (10,796) | | | (17,756) |
| Amortization of premiums and accretion of discounts on Investment securities | | | (904) | | | (1,220) |
| Other non-cash expenses | | | 932 | | | 1,126 |
| Change in operating assets and liabilities: | | | | |||
| Trade receivables | | (9,948) | | (9,017) | ||
| Inventory | | 1,098 | | (280) | ||
| Prepaid expenses and other assets | | (5,586) | | (4,004) | ||
| Trade payables | | 14,557 | | 3,555 | ||
| Other liabilities | | (12,483) | | (25,095) | ||
| Net cash provided by operating activities | | 113,314 | | 73,758 | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | | | ||||
| Purchase of investment securities | | | (43,032) | | | (46,317) |
| Proceeds from maturities and sales of investment securities | | | 40,937 | | | 44,481 |
| Purchase of property and equipment | | (132) | | (637) | ||
| Acquisition of Epygenix Therapeutics, Inc., net of cash acquired | | | — | | | (33,069) |
| Payment of upfront fee related to research collaboration, option and license agreement | | (15,000) | | (25,500) | ||
| Net cash used in investing activities | | (17,227) | | (61,042) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | | | ||||
| Principal repayment of long-term debt | | | (7,500) | | | (7,500) |
| Payments of employee withholding taxes related to stock-based awards | | | (2,341) | | | (269) |
| Proceeds from exercised options | | 6,803 | | 689 | ||
| Net cash used in financing activities | | (3,038) | | (7,080) | ||
| NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | | 93,049 | | 5,636 | ||
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—Beginning of period | | 453,271 | | 311,930 | ||
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—End of period | | $546,320 | | $317,566 | ||
| Supplemental Disclosure of Cash Flow Information: | | | ||||
| Cash paid during the year for interest | | $7,660 | | $8,944 | ||
| Cash paid during the year for taxes | | | 35,371 | | | 42,093 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.